The global embolotherapy market was valued at USD 3,600.0 million in 2020 and is expected to grow at a CAGR of 6.8% during the forecast period (2021–2027). The market is growing significantly due to the extensive incidences of liver cancer, uterine fibroids, vascular diseases, strokes along with technological progressions being undertaken in this market. Furthermore, increasing preference pertaining to nominally invasive processes and excessive funds, grants and investments availed to key players by public-private enterprises for research are another factors that are bolstering the growth of global embolotherapy market at a significant rate.

Embolotherapy is a form of endovascular treatment that intends to obstruct abnormal blood vessels for controlling bleeding, devascularise organs, arteriovenous malformations and close fistulae. Furthermore, embolotherapy is performing crucial role in medicine domain that aims at the accomplishment of occlusion and utilises various embolic agents and minimally invasive techniques for instance coils, gelfoam, angiographic, balloons and catheters. This technique helps in treating wide range of problems and utilises varies therapies such as UFE, TACE and venous embolisation for the treatment of arthritis embolization and haemorrhoid and is further witnessing technological progressions that is contributing towards rampant growth of global embolotherapy market.

Increasing target population of patient along with extensive preference of patients for minimally invasive techniques are the key factors that are driving the growth of global embolotherapy market. Several patients across the globe require embolotherapy processes for treating several diseases for instance liver cancer tumors, kidney cancer, hepatocellular, renal cell carcinoma, aneurysms and varicose veins. Moreover, embolotherapy has wider usage in clinical settings such as in the treatment of non-trauma related vascular disorders and treatment of inflammation that is significantly contributing towards the growth of the global embolotherapy market.

Request to get free sample copy at: https://www.vynzresearch.com/healthcare/embolotherapy-market/request-sample

North America has accounted for the largest share in embolotherapy market, globally and is predicted to grow significantly during the forecast period, owing to the increasing emphasis in the region towards development of advanced embolic agents, extensive pervasiveness of incidents that necessitates adoption of embolization processes. Moreover, established healthcare system in this region is the key factor that is further anticipated to drive the growth of embolotherapy market in this region.

Moreover, embolotherapy market in Asia-Pacific is anticipated to witness fastest growth during the forecast period owing to the increasing number of patient’s population, increasing emphasis by the government authorities in the region towards healthcare expenditure and rapid incidences of cancer among individuals. Additionally, presence of key players emphasizing upon technological advancements are the key factors that are pertaining towards the growth of embolotherapy market in this region.

The eminent key players in the global embolotherapy market are undertaking considerable investment decisions and launching new products in order gain competitive advantage. Moreover, entering into partnership agreements and performing mergers & acquisitions are the key development strategies being implemented by the crucial players in the global embolotherapy market.

Some of the players having prominent presence in the global embolotherapy market include Merit Medical Systems, Acandis GmbH, Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Cook Medical, Terumo Corporation, Stryker Corporation, Johnson & Johnson, BALT Extrusion, Sirtex Medical Limited, Kaneka Corporation, Meril Life Sciences Pvt. Ltd., Penumbra, Inc., and BTG Plc.

Source: VynZ Research